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ARTICLE

Identification of monocyte-like precursors of
granulocytes in cancer as a mechanism for
accumulation of PMN-MDSCs
Jérôme Mastio1, Thomas Condamine1, George Dominguez1,2, Andrew V. Kossenkov1, Laxminarasimha Donthireddy1, Filippo Veglia1, Cindy Lin1,
Fang Wang1, Shuyu Fu1,3, Jie Zhou3, Patrick Viatour4, Sergio Lavilla-Alonso1, Alexander T. Polo2, Evgenii N. Tcyganov1, Charles Mulligan Jr.5,
Brian Nam5, Joseph Bennett5, Gregory Masters5, Michael Guarino5, Amit Kumar2, Yulia Nefedova1, Robert H. Vonderheide6, Lucia R. Languino7,
Scott I. Abrams8, and Dmitry I. Gabrilovich1

We have identified a precursor that differentiates into granulocytes in vitro and in vivo yet belongs to the monocytic lineage.
We have termed these cells monocyte-like precursors of granulocytes (MLPGs). Under steady state conditions, MLPGs were
absent in the spleen and barely detectable in the bone marrow (BM). In contrast, these cells significantly expanded in tumorbearing mice and differentiated to polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs). Selective depletion of
monocytic cells had no effect on the number of granulocytes in naive mice but decreased the population of PMN-MDSCs in
tumor-bearing mice by 50%. The expansion of MLPGs was found to be controlled by the down-regulation of Rb1, but not
IRF8, which is known to regulate the expansion of PMN-MDSCs from classic granulocyte precursors. In cancer patients,
putative MLPGs were found within the population of CXCR1+CD15−CD14+HLA-DR−/lo monocytic cells. These findings describe a
mechanism of abnormal myelopoiesis in cancer and suggest potential new approaches for selective targeting of MDSCs.

Introduction
There is now ample evidence suggesting that the success of
cancer immunotherapies and even more traditional methods of
treatment, such as radiation and chemotherapy, heavily depend
on myeloid cells in the tumor microenvironment (Coussens and
Pollard, 2011; Galdiero et al., 2013). In cancer, one of the most
prominent changes in the myeloid compartment is the expansion of pathologically activated immature myeloid cells, termed
myeloid-derived suppressor cells (MDSCs), with the potent
ability to suppress immune responses. Besides suppressing antitumor immunity, MDSCs also stimulate other aspects of tumor
growth including tumor angiogenesis, tumor cell invasion, and
formation of premetastatic niches (Condamine et al., 2015).
MDSCs are directly implicated in negatively impacting patient
responses to cancer therapies (Diaz-Montero et al., 2009;
Arihara et al., 2013; Chen et al., 2014; Kawano et al., 2015;
Romano et al., 2015; Lee et al., 2016; Tada et al., 2016; Wang et al.,
2016; Wang and Yang, 2016), including immunotherapies

(Kimura et al., 2013; Martens et al., 2016; Sade-Feldman et al.,
2016; Weber et al., 2016; Butterfield et al., 2017; de Coaña et al.,
2017).
In tumor-bearing (TB) mice, the population of MDSCs consists of two large groups of cells: the most abundant (>75%)
population consists of pathologically activated neutrophils,
CD11b+Ly6CintLy6G+ polymorphonuclear MDSCs (PMN-MDSCs),
while the less abundant (<20%) population consists of
CD11b+Ly6ChiLy6G− pathologically activated monocytes: monocytic MDSCs (M-MDSCs; Bronte et al., 2016). The current prevailing view is that M-MDSCs and PMN-MDSCs differentiate
along the same pathways as monocytes and neutrophils, respectively, and their expansion in cancer is controlled by increased production of GM-CSF, CSF-1, and other growth factors
(Gabrilovich et al., 2012). These pathways involve pluripotent
hematopoietic stem cells, multipotent common myeloid progenitors (CMPs), and granulocyte-macrophage progenitors
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(GMPs). Recently, several populations of committed granulocytic precursors (GPs) were identified (Waight et al., 2013;
Yáñez et al., 2015; Evrard et al., 2018). Down-regulation of the
IRF8 transcription factor, which is important for the switch
between monocytic and granulocytic cell differentiation
(Kurotaki et al., 2014), was directly implicated in the expansion
of PMN-MDSCs from GPs (Netherby et al., 2017).
We previously obtained evidence that M-MDSCs from TB
mice were able to differentiate into PMN-MDSCs, suggesting
that, in cancer, some monocytic cells can be redirected to differentiate into granulocytes (Youn et al., 2013). Down-regulation
of the retinoblastoma 1 (Rb1) gene was implicated in this process.
The concept of Rb1 involvement in PMN-MDSC differentiation
was supported in more recent studies using a breast cancer
mouse model (Casbon et al., 2015). However, only a portion of
the M-MDSC population was found to be able to differentiate
into granulocytes. This raised the question of whether the
M-MDSC population contained some GPs rather than a demonstrated abnormal switch in lineage commitment. The contribution of these cells to the pool of PMN-MDSCs was also not
known. In this study, we sought to address these questions. We
have demonstrated that abnormal myelopoiesis in TB mice, and
to some extent in cancer patients, manifests in the expansion of
a defined population of monocyte-like precursors of granulocytes (MLPGs). We identified the phenotype and the nature
of these cells and determined that, at least in two murine tumor
models, these cells contributed up to half of the total pool of
PMN-MDSCs.

Results
Identification of MLPGs in TB mice
To better characterize the population of M-MDSCs in TB mice,
we used Rb1 reporter mice, which were generated by inserting
the eGFP cassette at the start codon of the Rb1 gene. eGFP expression paralleled that of Rb1 in most of the organs surveyed,
including the spleen and the lungs, along with Gr-1+CD11b+
cells and T and B lymphocytes (Burkhart et al., 2010). Inflammatory monocytes in the bone marrow (BM) of EL-4 TB
mice were defined using a standard set of phenotypic markers: CD11b+Ly6ChiLy6G− (Bronte et al., 2016). These cells had a
heterogeneous expression of Rb1, with most cells expressing
high levels of Rb1 and ∼30% having relatively low expression
levels (Fig. 1 A). BM and splenic CD11b+Ly6ChiLy6G− cells in
TB mice had a substantially lower Rb1 expression than the
cells with the same phenotype in naive mice (Fig. 1 B), reflecting a lower proportion of Rb1lo monocytes in naive mice
(Fig. 1 C).
Rb1lo and Rb1hi CD11b+Ly6ChiLy6G− monocytes from the BM
of TB mice were cultured for 3 d with GM-CSF and tumor explant supernatant (TES) to determine whether these two cell
populations differentiate into similar or different cell types.
More than 85% of the cells differentiated from Rb1lo monocytes
had a CD11b+Ly6CintLy6G+ granulocytic phenotype. In contrast,
only ∼5% of cells differentiated from Rb1hi monocytes had the
same granulocytic phenotype (Fig. 1 D). Rb1 expression was
closely associated with the expression of CD117 (c-kit). Most of
Mastio et al.
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the Rb1lo but not the Rb1hi monocytic cells expressed CD117 (Fig. 1 E).
In TB mice, CD117+CD11b+Ly6ChiLy6G− monocytic cells had a
low Rb1 expression, which was only marginally higher than
the level found in CD11b+Ly6CintLy6G+ PMN-MDSCs, whereas
the CD117−CD11b+Ly6ChiLy6G− monocytic cells had almost a
threefold higher Rb1 expression than PMN-MDSCs (Fig. 1 F).
Next, we investigated whether CD117+Rb1lo and CD117−Rb1hi
CD11b+Ly6ChiLy6G− monocytic cells had the suppressive activity
usually attributed to M-MDSCs. CD117+ monocytic cells had no
T cell suppressive activity, whereas CD117− cells had a potent
suppressive activity (Fig. 1 G). Thus, these two populations have
different functional properties: CD117−CD11b+Ly6ChiLy6G− cells
were bona fide M-MDSCs, whereas CD117+CD11b+Ly6ChiLy6G−
cells were not suppressive but could differentiate to granulocytes.
We then performed an in vitro differentiation experiment with sorted BM monocytic cells based on CD117
expression. Within 3 d in culture with GM-CSF and TES,
CD11b+Ly6ChiLy6G−CD117+ monocytic cells differentiated to
cells with the phenotype (Fig. 1 H) and morphology (Fig. 1 I) of
granulocytes, whereas the CD11b+Ly6ChiLy6G−CD117− monocytic cells remained Ly6G− and differentiated to CD115+ cells
represented by F4/80+ macrophages and dendritic cells (Fig. 1,
H and I). Similar results were obtained when these cells were
cultured with CSF-1 (M-CSF; Fig. 1 H). To trace the fate of
CD11b+Ly6ChiLy6G−CD117+ monocytic cells in vivo, these cells
were sorted from the BM of EL-4 TB CD45.2+ mice and transferred to sublethally irradiated CD45.1+ EL-4 TB congenic recipients. 3 d after the transfer, almost all CD45.2+ cells had the
phenotype of granulocytes (CD11b+Ly6CintLy6G+; Fig. 1 J). Taken
together, these results indicated that CD11b+Ly6ChiLy6G−CD117+
monocytic cells with a low Rb1 expression represented the
population of monocytic cells without suppressive activity but
with potent ability to differentiate to granulocytes. We provisionally designated these cells as MLPGs. In contrast,
CD11b+Ly6ChiLy6G−CD117− monocytic cells with a high Rb1 expression had a potent suppressive activity and differentiated
into macrophages and dendritic cells, thus fitting the common
definition of M-MDSCs.
The monocytic nature of MLPGs
CCR2+ differentiated monocytes with typical morphology represented most of the CD11b+Ly6ChiLy6G−CD117− M-MDSCs
(Fig. 2, A and B). In contrast, CD11b+Ly6ChiLy6G−CD117+ MLPGs
were mostly CCR2− (Fig. 2 A) and had morphology of immature
cells with less condensed chromatin and a ring-shaped nucleus
(Fig. 2 B). In the BM of TB mice, in addition to the populations
of CD11b+Ly6G−Ly6Chi M-MDSCs and MLPGs, cells with
CD11b+Ly6G−Ly6Cint phenotype were readily detectable (Fig. 2
C). The criterion to define Ly6C expression as high or intermediate was the level of Ly6C expression in Ly6G+ neutrophils.
Expression of Ly6C above the level observed in neutrophils was
considered as high, and at similar or lower levels than in neutrophils was considered as intermediate. To better characterize
CD11b+Ly6G−Ly6Cint cells, we used the CCR2 marker of mature
monocytes and the SiglecF marker of eosinophils/neutrophils
(Stockwell et al., 2017). While CD11b+Ly6G−Ly6Chi cells were
largely CCR2+SiglecF−, the CD11b+Ly6G−Ly6Cint cells were
Journal of Experimental Medicine
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Figure 1. Identification of monocytic precursors of granulocytes in TB mice. (A) Rb1 expression in CD11b+Ly6ChiLy6G− monocytic cells in BM of EL-4 TB
Rb1-GFP reporter mice assessed by flow cytometry. Numbers in the plots indicate the percentage of gated cells. Typical example of three experiments is
shown. (B) Rb1 expression in CD11b+Ly6ChiLy6G− monocytic cells in BM and spleens of TB and naive Rb1-GFP reporter mice. Mean and SD are shown of 13 TB
and 13 tumor-free mice. P values were calculated by two-tailed Student’s t test. ****, P < 0.0001. (C) Rb1 expression in CD11b+Ly6ChiLy6G− monocytic cells in
BM of naive Rb1-GFP reporter mice assessed by flow cytometry. Numbers in the plots indicate the percentage of gated cells. Typical example of three experiments is shown. (D) Phenotype of cells recovered after 3 d of culture with GM-CSF and TES of Rb1lo and Rb1hiCD11b+Ly6ChiLy6G− monocytic cells isolated
from BM of EL-4 TB Rb1-GFP reporter mice. Numbers in the plots indicate the percentage of gated cells. Typical example of four experiments is shown. (E) Rb1
and CD117 expression in CD11b+Ly6ChiLy6G− monocytic cells from BM of EL-4 TB Rb1-GFP reporter mice assessed by flow cytometry. Numbers in the plots
indicate the percentage of gated cells. Typical example of 13 experiments is shown. (F) Rb1 expression in CD117+ and CD117−CD11b+Ly6ChiLy6G− monocytic
cells and CD11b+Ly6CintLy6G+ PMN-MDSCs in BM of EL-4 TB Rb1-GFP reporter mice. Mean and SD of three experiments are shown. *, P < 0.5; **, P < 0.01; ***,
P < 0.001 by two-tailed Student’s t test. MFI, mean fluorescence intensity. (G) Antigen-specific proliferation of CD8+ T cells in the presence of Rb1lo and
Rb1hiCD11b+Ly6ChiLy6G− monocytic cells sorted from BM of EL-4 TB Rb1-GFP reporter mice. Proliferation was measured in triplicate by 3H thymidine uptake.
PMEL T cells were used as responder cells in this antigen-specific suppression assay. No st., no stimulation; Pept., stimulation of splenocytes with gp
100–derived peptide. Mean and SD of typical example of three experiments is shown. **, P < 0.01 by two-tailed Student’s t test. Three experiments with the
same results were performed. (H) Phenotype of cells recovered after 3 d of culture with GM-CSF and TES or M-CSF of CD117+ and CD117−CD11b+Ly6ChiLy6G−
monocytic cells sorted from BM of EL-4 TB mice. Numbers in the plots indicate the percentage of gated cells. Typical example of three experiments is shown.
(I) Wright-Giemsa staining of cells differentiated with GM-CSF and TES from indicated precursors. Scale bar, 20 µm. Typical example of three experiments is
shown. (J) In vivo differentiation of CD45.2+CD117+CD11b+Ly6ChiLy6G− monocytic cells transferred to sublethally irradiated EL-4 TB CD45.1+ recipient. Typical
example of two experiments is shown. CPM, counts per minute; SSC, side scatter.
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Figure 2. The monocytic nature of MLPGs. (A) CCR2 expression in CD117− and CD117+CD11b+Ly6ChiLy6G− M-MDSCs and MLPGs in BM of EL-4
TB mice assessed by flow cytometry. Numbers in the plots indicate the percentage of gated cells. Typical example of three experiments is shown.
(B) May-Grünwald-Giemsa staining of CD117−CD11b+Ly6ChiLy6G− M-MDSCs, CD117+CD11b+Ly6ChiLy6G− MLPGs, CD117+CD11b+Ly6CintLy6G− GPs, and
Lin−Sca-1−CD117+CD34+CD16/32hi GMPs sorted from BM of EL-4 TB mice. Scale bar, 20 µm. (C) CCR2 and SiglecF expression in Ly6Chi and
Ly6CintCD11b+Ly6G− populations in BM of EL-4 TB mice assessed by flow cytometry. Numbers in the plots indicate the percentage of gated cells. Typical
example of three experiments is shown. (D) Comparison of the transcriptomes of CD11b+Ly6ChiLy6G−CD117+ MLGP and CD11b+Ly6CintLy6G−CD117+ GPs
from BM of EL-4 TB mice with transcriptomic profiles of different populations of hematopoietic cells and progenitors from the Immgen website. Cell
types from the Immgen Consortium whose expression profiles correlated the most with MLPGs and GPs are shown. (E) tSNE clustering of granulocytes
and monocytes with MLPGs and GPs. *, intermediate; 6C, Ly6C; Arth, arthritic; bl, blood; GN, granulocytes; II, MHCII; Mo, monocytes; PC, peritoneal
cavity; SSC, side scatter; SF/SynF, synovial fluid; Thio, thioglycolate; UrAc, uric acid.

largely CCR2−, with >30% SiglecF+ cells (Fig. 2 C). A previous
study identified a population of Ly6C+CD117+LKS−CD34+FcγRhi
cells as committed granulocytic progenitors (Yáñez et al.,
2015). Ly6C expression in these cells could be characterized
as intermediate. In contrast to that granulocyte progenitor
population, in our experiments, MLPGs expressed high Ly6C
Mastio et al.
Monocytic precursors of granulocytes in cancer

and CD11b and had a morphology of more advanced GPs, with
a ring-shaped nucleus (Fig. 2 B). Also, the morphology of
MLPGs was different from that of more upstream granulocyte progenitors such as GMPs (Fig. 2 B). The fact that GMPs
do not express CD11b and had low or no expression of Ly6C
indicates that MLPGs and GMPs are quite distinct cells.
Journal of Experimental Medicine
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CD11b+Ly6CintCCR2−SiglecF−Ly6G−CD117+ cells had similar
characteristics as the late GPs, specifically the preneutrophil (preNeu) population, described recently in another
study (Evrard et al., 2018). To confirm that CD11b + Ly6
CintCCR2−SiglecF−Ly6G−CD117+ indeed represented GPs, these
cells were sorted from the BM of TB mice and were cultured
for 3 d with GM-CSF. Practically all cells generated from
those precursors had the phenotype and morphology of granulocytes (Fig. S1 A). To verify these findings in vivo,
CD45.2+CD11b+Ly6CintCCR2−SiglecF−Ly6G−CD117+ cells from the
BM of EL-4 TB mice were transferred to sublethally irradiated
congenic CD45.1+ EL-4 TB recipients. Within 3 d after the
transfer, most donor cells became CD11b+Ly6CintLy6G+ granulocytes (Fig. S1 B).
The next question was whether MLPGs could differentiate
into GPs. To address this question, we sorted MLPGs (with >95%
purity) from the BM of CD45.2+ EL-4 TB mice and transferred
them to sublethally irradiated CD45.1+ EL-4 TB recipient mice.
3 h after the transfer, only a few CD45.2+Ly6CloLy6G+ donor
PMNs were detected in recipient spleens, and practically all
donor cells were still Ly6Chic-kit (CD117)+. 24 h later, all Ly6Chi
donor cells had disappeared. Half of the donor cells were Ly6G+
PMNs. However, no more Ly6Cloc-kit+ cells were detected (Fig.
S1 C). After 48 h, all donor cells became PMNs. In contrast, a GP
population was clearly detectable in CD45.1+ host cells (Fig. S1 C).
These data suggest that MLPG differentiation to PMNs in vivo
does not include the GP stage.
The major question about MLPGs was whether these cells
indeed belonged to the monocytic lineage or were cells of
granulocytic lineage that had high expression of the Ly6C
marker. To address this question, we compared the whole
transcriptome of MLPGs and GPs from the BM of EL-4 TB mice
with those of different cell populations defined by the Immgen
Consortium. When all expressed genes in MLPGs were analyzed,
their expression profile correlated with monocytes, macrophage
dendritic cell progenitors (MDPs), and common dendritic cell
progenitors. In contrast, GPs correlated only with the genes
expressed in granulocytes (Fig. 2 D). Based on clustering analysis
of granulocytes and monocytes from Immgen along with GPs
and MLPGs, MLPGs showed clear association with monocytes,
while GPs clustered with granulocytes (Fig. 2 E). The top genes
differentially expressed between MLPGs and GPs that overlapped with genes specific to granulocytes and monocytes
are shown in Fig. S2 A. We compared the expression profile of MLPGs and GPs with populations of BM and
spleen CD11b+Ly6CintLy6G+ neutrophils/PMN-MDSCs and
CD11b+Ly6ChiLy6G− monocytes/M-MDSCs isolated from naive
and EL4-TB mice that have been characterized previously
(Youn et al., 2012). The gene expression of GPs clustered closely
with the profile of neutrophils/PMN-MDSCs, whereas MLPGs
correlated closely with monocytes/M-MDSCs (Fig. S2 B). We
also compared the genomic signatures of different populations
of GPs, including GMPs, as well as the preNeu population
(Evrard et al., 2018), with GPs and MLPGs from our study. The
RNA sequencing (RNA-seq) data for GMPs, preNeu, and immature neutrophils were downloaded from Gene Expression
Omnibus (accession no. GSE109467; Evrard et al., 2018). Genes
Mastio et al.
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were overlapped with microarray data using Entrez IDs, and
differentially expressed genes between GPs and MLPGs (n =
248) with false discovery rate (FDR) <5% were normalized to
average within each dataset. Principal component analysis was
used to cluster the data using principal components obtained
from GP/MLPG samples. We observed that GPs were close to
preNeu and GMPs, whereas MLPGs were quite distinct (Fig.
S2 C).
The chemokine receptor CX3CR1 is a marker specific for the
monocytic lineage. Using reporter mice with a Cx3cr1-driven
expression of egfp, we assessed the expression of CX3CR1 in
the MLPGs from the BM of TB mice. As a positive control
for CX3CR1 expression, we used CD11b+Ly6CloLy6G−CD117−
spleen patrolling monocytes, and as negative control,
CD11b+Ly6CintLy6G+ neutrophils. MLPGs expressed CX3CR1 at
levels comparable to that of M-MDSCs, whereas GPs expressed
CX3CR1 at levels similar to those found in PMN-MDSCs (Fig. 3
A). Dot-plot analysis of CX3CR1 expression in c-kit− M-MDSCs
and c-kit+ MLPGs demonstrated a homogeneous expression of
CX3CR1 among MLPGs, without cells having especially high or
low CX3CR1 expression. The overall pattern of CX3CR1 expression was similar between M-MDSCs and MLPGs (Fig. 3 B).
This supports the conclusion that MLPGs are a homogeneous
population of cells. In addition, BM-derived MLPGs failed to
form colonies in myeloid colony-forming assays. Taken together, these results indicated that MLPGs belong to the
monocytic lineage of cells and can differentiate almost exclusively to granulocytes.
To clarify the origin of MLPGs, we tested whether GMPs can
produce neutrophils through the MLPG stage. GMPs were sorted
from the BM of CD45.2+ EL4 TB mice using established phenotypic criteria (Fig. 3 C). Sorted GMPs were then injected i.v. into
sublethally irradiated CD45.1+ EL-4 TB recipient mice. 24 h later,
among the donor cells, ∼30% of CD11b+Ly6ChiLy6G− cells had the
phenotype of MLPGs, suggesting that the MLPGs were downstream of the GMPs (Fig. 3 D).
CD115 is a marker of monocytic cells. We studied the expression of CD115 in MLPGs from EL-4 TB mice. CD115− cells
represented 90% and CD115+ 10% of all MLPGs (Fig. 4 A). We
hypothesized that CD115+ and CD115− MLPGs may represent
different stages of differentiation to granulocytes. To test this
hypothesis, CD115+ and CD115− MLPGs were sorted from the BM
of EL-4 TB mice and cultured for 3 d in the presence or absence
of TES. More than 80% of cells that differentiated from CD115−
MLPGs in the presence of TES were CD115−Ly6G+ granulocytes,
with CD115+Ly6G− monocytic cells representing only a small
fraction of cells (Fig. 4 B). Absence of TES in culture did not
affect those proportions. In contrast, cells differentiated from
CD115+ MLPGs in the presence of TES were equally split between
CD115+Ly6G− monocytic and CD115−Ly6G+ granulocytic cells
(Fig. 4 B). All monocytic cells also expressed the macrophage
marker F4/80. In the absence of TES, the proportion of monocytic/macrophage cells differentiated from CD115+ MLPGs increased to 70% and granulocytic cells reduced to 10% (Fig. 4 B).
These data indicate that CD115− MLPGs represent committed
precursors, whereas differentiation of CD115+ MLPGs could be
reverted to monocyte/macrophage lineage in the absence of
Journal of Experimental Medicine
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Figure 3. The nature of MLPGs. (A) CX3CR1 expression in CD117−CD11b+Ly6ChiLy6G− M-MDSCs, CD117+CD11b+Ly6ChiLy6G− MLPGs, CD117+CD11b+Ly6CintLy6G−
GPs, and CD11b+Ly6CintLy6G+ PMN-MDSCs in BM of CX3CR1-GFP+ EL-4 TB mice. As a positive control, CD117−CD11b+Ly6CintLy6G− monocytes were used. Top:
Typical example of staining. Bottom: Mean and SD from five mice per group are shown. ****, P < 0.0001 by two-tailed Student’s t test. MFI, mean fluorescence
intensity. (B) Pattern of CX3CR1 expression in MLPGs in EL-4 TB mice. CX3CR1 expression in CD11b+Ly6ChiLy6G− monocytic cells in BM of EL-4 TB CX3CR1
reporter mice assessed by flow cytometry. Numbers in the plots indicate the percentage of gated cells. Expression of CX3CR1 is shown for individual mice (n = 5).
(C and D) Differentiation of CD45.2+ GMPs isolated from the BM of EL-4 TB mice after adoptive transfer to sublethally irradiated CD45.1+ EL-4 TB recipient mice.
CD45.2+ donor cells were evaluated by flow cytometry in spleens of CD45.1+ recipient mice after 24 h. (C) Phenotype of cells before transfer. (D) Phenotype of
cells differentiated from the donor’s GMPs 24 h after transfer. Two experiments with the same results were performed. SSC, side scatter.
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Figure 4. Differentiation of MLPGs. (A) Example of gating strategy and proportion of CD115+ cells among CD11b+Ly6ChiLy6G−CD117+ MLPGs from BM of
EL4-TB mice. Three mice were evaluated. The results of individual experiments, mean and SD, are shown. (B) CD115− and CD115+ MLPGs were sorted from the
BM of EL-4 TB mice and cultured for 3 d with GM-CSF with or without TES (20% vol/vol). The frequencies of CD115+Ly6G− monocytic cells and of CD115−Ly6G+
granulocytic cells obtained upon differentiation of both subsets of MLPGs are shown. The results of individual experiments (n = 5), mean and SD, are shown. **,
P < 0.01; ****, P < 0.0001 by two-tailed Student’s t test. (C) CX3CR1 expression was measured using naive reporter mice in the indicated cell populations. The
results of individual experiments (n = 3), mean and SD, are shown. *, P < 0.05; ***, P < 0.001; ****, P < 0.0001 by two-tailed Student’s t test. MFI, mean
fluorescence intensity. (D) Example of phenotype of cells recovered after 3 d of culture with GM-CSF of CD11b+Ly6ChiLy6G−CD117− monocytes and
CD11b+Ly6ChiLy6G−CD117+ MLPGs sorted from BM of naive mice. Numbers in the plots indicate the percentage of gated cells. (E) Numbers of cells generated
from naive or EL-4 BM MLPGs after 3-d culture in complete RPMI with GM-CSF. Results of five experiments are shown. *, P < 0.05. (F) Antigen-specific
proliferation of CD8+ T cells in the presence of Ly6G+ cells isolated after cultures of naive or EL-4 TB BM MLPGs. Cultures were done with GM-CSF and
additional TES for EL-4 BM MLPGs. Proliferation was measured in triplicate by 3H thymidine uptake. PMEL T cells were used as responder cells in this antigenspecific suppression assay. Mean and SD are shown. Two experiments with similar results were performed. *, P < 0.05; ***, P < 0.001 by two-tailed Student’s
t test. No stim, no stimulation; cpm, counts per minute; SSC, side scatter.

tumor-derived factors. Expression of CX3CR1 in CD115+ MLPGs
was similar to that in monocytes, whereas in CD115− it was
significantly lower but still threefold higher than in neutrophils
(Fig. 4 C).
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Although naive mice contained a very small amount of
MLPGs in the BM, these cells could differentiate into granulocytes in vitro (Fig. 4 D). However, on a per-cell basis, the
number of granulocytes generated from MLPGs in TB mice was
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significantly (P = 0.04) higher than from MLPGs in naive mice
(Fig. 4 E). We tested the ability of MLPGs from control or TB
mice to generate immunosuppressive PMN-MDSCs. MLPGs
were isolated from the BM of naive or EL-4 TB mice and cultured
for 3 d in the presence of GM-CSF without or with TES, respectively. At the end of the culture, granulocytes generated
from the precursors were purified and tested in an antigenspecific suppression assay. Granulocytes generated from
MLPGs of EL-4 TB mice had a stronger suppressive activity than
granulocytes generated from MLPGs of control mice (Fig. 4 F).
Expansion of MLPGs in TB mice and their contribution to
PMN-MDSC accumulation
Next, we compared the presence of MLPGs in BM and spleens of
naive and TB mice using different transplantable and genetically
engineered tumor models (GEMs). The presence of MLPGs in the
BM of naive C57BL/6 and BALB/c mice was very low (Fig. 5, A
and B), and in the spleens, these cells were practically undetectable (Fig. 5 C). In all tested transplantable tumor models in
C57BL/6 mice (EL-4 lymphoma, LL2 lung adenocarcinoma, and
B16F10 melanoma; Fig. 5 A) and in Balb/c mice (CT26 colon
carcinoma; Fig. 5 B), the number of MLPGs in BM was increased
two- to sixfold, and these cells were readily detectable in spleens
(Fig. 5 C). This was associated with a substantial accumulation of
PMN-MDSCs in spleens (Fig. 5, A and B). A modest increase in
BM MLPGs in the B16F10 model of melanoma was associated
with a relatively modest up-regulation of spleen PMN-MDSCs
(Fig. 5 A). In addition, the Ret melanoma (Kato et al., 1998),
transgenic adenocarcinoma mouse prostate (TRAMP) prostate
(Greenberg et al., 1995), and KrasG12DTrp53R172HPdx-1 (KPC)
pancreatic (Bayne et al., 2012) GEMs were used. In KPC mice, a
significant (P < 0.01) up-regulation of BM and spleen MLPGs
was associated with a substantial increase of spleen PMNMDSCs (Fig. 5 D). In TRAMP mice, the little changes in BM
and spleen MLPGs were associated with a minimal accumulation
of PMN-MDSCs (Fig. 5 E), whereas a modest BM and spleen
MLPG increase in Ret melanoma mice was associated with a
small accumulation of spleen PMN-MDSCs (Fig. 5 F). We performed a regression analysis of the absolute numbers of BM
MLPGs and spleen PMN-MDSCs across the different C57BL/6
tumor models described above. The absolute number of BM
MLPGs closely and positively correlated with the expansion of
spleen PMN-MDSCs (P = 0.007; Fig. 5 G). The increased presence of MLPGs was observed not only in cancer but also in an
experimental model of colitis, which was associated with neutrophil expansion (Fig. S3 A).
Since MLPGs were detected in naive mice (albeit in much
smaller numbers), we assessed the characteristics of these cells.
MLPGs from tumor-free mice also had a ring-shaped nucleus, a
morphology similar to the one seen for MLPGs from TB mice
(Fig. S3 B). Similarly to MLPGs from TB mice, naive MLPGs
expressed very little CCR2 (Fig. S3 C), were positive for CX3CR1
(Fig. S3 D), and did not suppress T cell response (Fig. S3 E).
Substantial accumulation of MLPGs in spleens of TB mice
raised the question of the role of the spleens in the expansion of
PMN-MDSCs in TB mice. To address this question, mice underwent either splenectomies or sham surgery followed by a
Mastio et al.
Monocytic precursors of granulocytes in cancer

long recovery period (10 wk) to eliminate the effect of surgical
stress on granulopoiesis. After that time, mice were injected s.c.
with LL2, B16F10, or KPC (G43.7) tumor cells. In all three models,
splenectomy did not affect the tumor growth (Fig. S4 A). On day
21 after inoculation of LL2 cells, the presence of different populations of myeloid cells was evaluated. There were no differences in the presence of MLPGs in the BM (Fig. S4 B), as well as
no differences observed in MDSCs and other myeloid cells in the
BM, blood, tumor, or liver (Fig. S4 C). A similar effect was seen
in the B16F10 melanoma model (Fig. S4 D). We isolated tumorassociated macrophages (TAMs), PMN-MDSCs, and M-MDSCs
from tumors and evaluated their suppressive activity. All three
populations from splenectomized and control mice (sham surgery) suppressed T cell function equally (Fig. S4 E). Thus, PMNMDSC expansion in TB mice was not restricted to the spleen,
with instead the BM playing the major role in the process.
What could be the contribution of MLPGs to the total pool of
neutrophils and PMN-MDSCs? We used CX3CR1CreER/GFP ×
ROSA26-DTRfl/fl mice to selectively deplete monocytic cells.
Treatment of these mice with tamoxifen (Tm) causes an upregulation of the diphtheria toxin (DT) receptor by cells expressing CX3CR1, rendering these cells susceptible to death after
diphtheria toxin injection. Since classic GPs, neutrophils, and
PMN-MDSCs do not express CX3CR1, we expected that only
MLPG-derived granulocytes would be affected in these mice.
Control and EL-4 TB mice were treated with Tm for 5 d, followed
by two administrations of DT (every other day) in addition to
Tm gavage (Fig. 6 A). In EL-4 or LL2 TB mice, Tm was administered after the mice exhibited palpable tumors. DT treatment
resulted in the depletion of monocytic cells in TB and tumor-free
mice (Fig. 6 B). Of note, to confirm monocyte depletion, we
compared DT-treated and untreated Cre+ mice, since these mice
have Cx3cr1-driven expression of Cre and GFP. In all other experiments described below, DT-treated Cre− mice served as
control. This treatment substantially decreased the number of
BM MLPGs but did not affect GPs (Fig. S5, A and B). In naive
mice, targeting MLPGs did not change the presence of granulocytes in the spleens (Fig. 6, C and D) or BM (Fig. 6, E and F).
Moreover, the number of these cells had a trend to increase. In
contrast, in EL-4 and LL2 TB mice, MLPG depletion significantly
reduced the proportion and total number of PMN-MDSCs in the
spleen (Fig. 6, C and D). Overall, the total number of PMNMDSCs was decreased by >50%. In the BM of TB mice, targeting MLPGs also caused a decrease in granulocytic cells; however,
it did not reach statistical significance (Fig. 6, E and F). It was
likely due to the fact that the BM normally contains a large
population of granulocytes that makes changes in TB mice difficult to detect. As expected, the population of M-MDSCs was
reduced in the spleen, but not in the BM of TB mice treated with
DT (Fig. 6 G). Lack of the effect in BM may be the result of a
faster turnover of these cells in the BM compared with the
spleen. After the treatment with DT, Cre+ TB mice had significantly smaller tumors than Cre− mice (Fig. 6 H).
To assess the impact of the DT treatment on tumor specific
immune response, we established OVA-expressing EL4 (EG7)
tumors s.c. in CX3CR1CreER− and CX3CR1Cre-ER+ Rosa-DTRfl/fl
mice. 10 d later, when tumor became palpable, mice were
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Figure 5. Population of MLPGs in TB mice. (A) Total cell number of MLPGs in BM and PMNs/PMN-MDSCs in spleens of naive or TB mice 3–4 wk after
subcutaneous inoculation of the indicated tumor cells to C57BL/6 mice. Results of individual mice are shown (5–12 mice per group). (B) Total cell number of
MLPGs in BM and PMNs/PMN-MDSCs in spleens of naive or CT26 TB mice BALB/c mice 3–4 wk after subcutaneous inoculation of the tumor cells. Results
of individual mice are shown (3–5 mice per group). (C) Total number of MLPGs in spleens of B16F10 and CT26 TB mice 3–4 wk after subcutaneous inoculation
of the tumor cells. Results of individual mice are shown (6–9 mice per group). (D) Total cell number of MLPGs in BM and spleens, and PMNs/PMN-MDSCs in
spleens of control (PC) or KPC mice. Results of individual mice are shown (three mice per group). (E) Total cell number of MLPGs in BM and spleens, and PMNs/
PMN-MDSCs in spleens of control or TRAMP mice. Results of individual mice are shown (three mice per group). (F) Total cell number of MLPGs in BM and
spleens, and PMNs/PMN-MDSCs in spleens of control or RET melanoma mice. 3–11 mice were used in each experiment, and the number of mice evaluated is
shown in each panel. Values of mean and SD are shown. *, P ≤ 0.05; **, P ≤ 0.01; ***, P < 0.001; ****, P ≤ 0.0001 by two-tailed Student’s t test. (G) Correlation
between total cell numbers of MLPGs in BM and total cell numbers of PMN-MDSCs in spleens in all C57BL/6 TB mice described above. Spearman coefficient
was used to calculate correlation.

treated with Tm for 8 d and DT on days 6 and 8. 1 d after that,
spleen CD8+ T cells were isolated and stimulated with the OVAderived SIINFEKL peptide, and their IFN-γ production was
measured in an ELISpot assay. We observed a strong response to
the peptide in Cre+ mice, whereas the response in Cre− mice was
barely detectable (Fig. 6 I). However, this effect may not necessarily argue for a specific role of PMN-MDSCs, since the
population of M-MDSCs in Cre+ mice was also decreased. These
results suggest that MLPGs do not contribute to the generation
of neutrophils in naive mice but are responsible for the accumulation of ≤50% of PMN-MDSCs in EL-4 and LL2 TB mice.
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Mechanisms of MLPG expansion in TB mice
Next, we investigated the possible specific role of Rb1 in MLPGs.
We assessed the number of MLPGs in the BM and spleens of
tumor-free Rb1−/− (Rb1 KO) mice, and mice with a deletion of all
three members of the pocket protein family (Rb1, p107, and p130;
triple KO [TKO] mice). The total numbers of MLPGs in both Rb1
KO and TKO mice increased more than twofold in the BM and
>6 times in the spleens (Fig. 7, A and B); these levels were very
similar to those observed in various tumor models, suggesting
that Rb1 could be a dominant factor in regulating MLPG accumulation. It is known that the IRF8 transcription factor plays an
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Figure 6. Contribution of MLPGs to PMN-MDSC accumulation in TB mice. (A) Schema of depletion of monocytic cells in CX3CR1CreER+ ROSA-DTRfl/fl EL-4
TB mice. (B) Example of flow cytometry analysis performed in blood samples from naive or EL-4 TB CX3CR1CreER+ ROSA-DTRfl/fl mice treated with Tm with or
without subsequent DT injection. Note the efficient depletion of CD11b+CX3CR1+Ly6Clo/− patrolling monocytes. (C and D) Results of individual mice are shown
in the figures (6–10 mice per group). Percentage (C) and total cell numbers (D) of PMNs/PMN-MDSCs in spleens of naive, EL-4, or LL-2 TB CX3CR1CreER− and
CX3CR1CreER+ ROSA-DTRfl/fl mice. (E and F) Results of individual mice are shown in the figures (five to six mice per group). Percentage (E) and total cell numbers
(F) of PMNs/PMN-MDSCs in BM of naive, EL-4, or LL-2 TB CX3CR1CreER− and CX3CR1CreER+ ROSA-DTRfl/fl mice. Result from each tested mouse as well as mean
and SD are shown. Individual P values (*, P < 0.05; **, P < 0.01; ***, P < 0.001) by two-tailed Student’s t test are shown. (G) M-MDSC population in
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CX3CR1CreER− and CX3CR1Cre-ER+ Rosa-DTRfl/fl LL2 TB mice. Total cell numbers of M-MDSCs in spleens and BM are shown. Result from each tested mouse (n = 7)
as well as mean and SD are shown. Individual P values (*, P < 0.05) by two-tailed Student’s t test are shown. (H) Tumor size in CX3CR1CreER− and
CX3CR1Cre-ER+ Rosa-DTRfl/fl EL-4 TB mice at day 16 at the time of sacrifice. Result from each tested mouse (n = 8–10) as well as mean and SD are
shown. Individual P values (*, P < 0.05) by two-tailed Student’s t test are shown. (I) EG7 tumors were established s.c. in CX3CR1CreER− and CX3CR1Cre-ER+ RosaDTRfl/fl mice. 10 d after tumor inoculation, when tumor became palpable, mice were treated with Tm (4 mg per day) for 8 d and DT injections (1 µg in 200 µl of
PBS) on days 6 and 8. 1 d after that, spleen CD8+ T cells were isolated and stimulated with the OVA-derived SIINFEKL peptide, and their IFN-γ production was
measured in an ELISpot assay (n = 3). P values were calculated by Student’s t test. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P ≤ 0.0001. SSC, side scatter.

important role in the switch between monocytic and granulocytic differentiation (Holtschke et al., 1996; Wang et al., 2014). Its
down-regulation was previously implicated in the accumulation
of PMN-MDSCs (Stewart et al., 2009; Waight et al., 2013;
Paschall et al., 2015). MLPGs, in contrast to monocytes, did not
express irf8 (Fig. 7 C). No difference in the expression of Rb1 was
found between MLPGs and GPs (Fig. 7 D). We compared the
effect of Rb1 and IRF8 deletion on the accumulation of MLPGs
and GPs. Rb1 and IRF8 KO mice demonstrated a similar substantial accumulation of neutrophils in the BM (Fig. 7 E).
However, the effect of their deletion on the populations of
MLPGs and GPs was opposite. Rb1 deletion caused a significant
(P = 0.03) increase in the population of MLPGs while not

affecting GPs, whereas IRF8 deletion resulted in a massive expansion of GPs but and a decrease of MLPGs (Fig. 7 F). We asked
whether Rb1-deficient GMPs produced more MLPGs. To address
this question, we injected CD45.1+ WT GMPs together with
CD45.2+ Rb1−/− GMPs to sublethally irradiated CD45.1+CD45.2+
recipient mice. On day 4, we assessed the frequencies of MLPGs
generated from CD45.1+ WT GMPs, CD45.2+ Rb1−/− GMPs, and
host CD45.1+CD45.2+ MLPGs. The frequency of MLPGs generated
from Rb1−/− GMPs was the same as from WT GMPs (Fig. S5, C
and D). These results not only underscore a specific role of Rb1 in
the regulation of MLPG expansion but also demonstrated distinct molecular mechanisms regulating the expansion of MLPGs
and GPs.

Figure 7. Rb1 regulates MLPG expansion while IRF8 controls GP accumulation. Results of individual mice are shown (5–11 mice per group). (A) Total cell
numbers of MLPGs in BM (left) and spleens (right) in WT or Rb1 KO naive mice. (B) Total cell numbers of MLPGs in BM (left) and spleens (right) in control mice
(p107+/−) or Rb TKO naive mice. (C) Expression of irf8 in MLPGs. Expression of irf8 (normalized to β-actin) in BM MLPGs from naive mice. Monocytes and
neutrophils are presented as controls. Gene expression was evaluated by quantitative RT-PCR in three independent experiments, each performed in triplicate.
Mean and SD of each measurement in triplicate is shown. (D) Rb1 expression in CD117+CD11b+Ly6ChiLy6G− MLPGs and CD117+CD11b+Ly6CintLy6G− GPs in BM
of EL-4 and LL2 TB Rb1-GFP reporter mice. Individual results and mean and SD are shown. P values were calculated by two-sided Student’s t test. MFI, mean
fluorescence intensity. (E) Total cell numbers of neutrophils in BM of WT mice and Rb1 KO or IRF8 KO mice. (F) Total cell numbers of MLPGs and GPs in BM of
WT mice and Rb1 KO or IRF8 KO mice. Mean and SEM are shown. In experiments with Rb1 KO mice, n = 6, and with IRF8 KO mice, n = 4. P values were
calculated by two-tailed Student’s t test. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001. (G) Growth of subcutaneous EL-4 tumor injected into WT
and Rb1 KO mice. Results in individual mice (n = 5) are shown. (H) Total cell numbers of BM and spleen MLPGs and GPs in WT and Rb1 KO EL-4 TB mice. Values
in individual mice (n = 5) and mean and SD are shown. P values were calculated by two-tailed Student’s t test. **, P < 0.01; ****, P < 0.0001. (I) Growth of
subcutaneous MC38 tumors injected into WT and Rb1 KO mice. Results in individual mice (n = 4) are shown. P value was calculated by two-way ANOVA.
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We next asked whether tumors could affect populations of
MLPGs and GPs in Rb1 KO mice. We found a modest increase in
tumor burden in EL-4 TB Rb1 KO mice compared with EL-4 TB
Rb1 WT mice (Fig. 7 G). The presence of MLPGs in BM in WT TB
mice, which was already elevated relative to the control level in
WT naive mice (as seen in Fig. 3), was not further increased in
Rb1 KO EL-4 TB mice (Fig. 7 H). However, in the spleens, the
total cell number of MLPGs and GPs was markedly expanded.
This was associated with an increased population of PMNMDSCs (Fig. 7 H). We asked whether the lack of substantial
increase in the tumor burden in EL-4 TB Rb1 KO mice was the
result of the relative low immunogenicity of the EL-4 tumor
model. To test this hypothesis, we used a more immunogenic
model, the MC38 tumor model, and observed a substantially
higher tumor growth in Rb1 KO mice than WT mice (Fig. 7 I).
To elucidate the mechanism of MLPG accumulation in TB
mice, we compared the proliferation and survival of MLPGs
from TB mice with those from naive mice. MLPGs from EL-4 TB
mice had a higher proliferation than MLPGs isolated from naive
mice (as assessed by BrdU uptake or 3H thymidine incorporation; Fig. 8 A). MLPGs from EL-4 TB mice had significantly (P =
0.0008) less apoptosis (Annexin V+ cells) after overnight culture
than MLPGs from naive mice (Fig. 8 B). The addition of TES
decreased apoptosis in both the naive and EL-4 TB MLPGs.
However, even in the presence of TES, MLPGs from TB mice
demonstrated significantly (P = 0.04) less apoptosis (Fig. 8 C).
MLPGs from tumor-free Rb1 KO mice demonstrated higher
proliferation in vitro (Fig. 8 D) and in vivo (Fig. 8 E) than MLPGs
from WT mice. In contrast, apoptosis of MLPGs from Rb1 KO
mice was only slightly reduced compared with MLPGs from
naive mice (Fig. 8 F). Thus, the decreased apoptosis together
with the increased proliferation contributed to the expansion of
MLPGs in cancer. Since Rb1 did not affect the survival of MLPGs,
there are likely other factors contributing to MLPG expansion in
cancer.
We investigated the cytokine requirements for survival and
differentiation of MLPGs in vitro. In the absence of cytokines
and serum, practically no live cells were found after 3 d of culture of MLPGs (Fig. 8, G and H). However, the presence of FBS
was sufficient to support the survival and expansion of MLPGs
and their differentiation to granulocytes (Fig. 8, G–I). Moreover,
the addition of G-CSF, M-CSF, or SCF did not change the total
number and the proportion of granulocytic cells generated in
culture; only GM-CSF provided modest improvement (Fig. 8 G).
In contrast, FBS was not sufficient to support survival of
M-MDSCs, and these cells required the presence of GM-CSF and
M-CSF (Fig. 8, G and H). We investigated the role of individual
growth factors in MLPG survival and differentiation using
serum-free medium. In the absence of FBS, MLPG survival and
expansion was not supported by any of the tested cytokines
alone (Fig. 8 J). The presence of lipids in serum was critical for
MLPG survival and differentiation, since lipid-depleted FBS did
not support MLPG survival and differentiation. In contrast to
serum-free medium, GM-CSF alone supported MLPG survival
and expansion in lipid-depleted medium (Fig. 8 G). Thus, yet
unidentified lipid factors in combination with GM-CSF were
required to support differentiation of MLPGs.
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Human monocytic cells contain MLPGs
We asked whether the human M-MDSCs could contain MLPGs.
To address this question, we sorted M-MDSCs and monocytes
from patients with advanced non–small cell lung cancer based
on established phenotypic criteria (CD15−CD14+HLA-DR−/low for
M-MDSCs and CD15−CD14+HLA-DRhigh for monocytes; Bronte
et al., 2016). Gene expression profiles were evaluated using
RNA-seq. Analysis of individual genes significantly differentially expressed in CD15−CD14+HLA-DR−/low cells compared with
monocytes (619 genes with FDR <5%) revealed a number of upregulated genes associated with neutrophil function: IL-8,
MNDA (myeloid cell nuclear differentiation antigen), CSF3R
(G-CSF receptor), LYZ (lysozyme), and NCF4 and NCF2
(neutrophil cytosolic factors 4 and 2). At the same time,
CD15−CD14+HLA-DR−/low cells demonstrated significant downregulation of several genes associated with monocytes/macrophages: CSF1R (M-CSF receptor), NR4A1 (Nur77), CX3CR1, ITGA4
(CD49d), and CD52 (Fig. 9 A). Function enrichment analysis revealed significant overrepresentation in CD15−CD14+HLA-DR−/low
cells of genes associated with various neutrophil functions
(Fig. 9 B). These results may suggest that CD15−CD14+HLADR−/low cells in patients with cancer may contain precursors
of neutrophils.
One notable gene that was up-regulated on M-MDSCs was
Cxcr1. This is a chemokine receptor expressed on neutrophils
and usually not associated with monocytes. We evaluated CXCR1
expression by flow cytometry and determined that monocytes
from healthy individuals and patients with prostate cancer had
very low expression of this protein, whereas almost 20% of
M-MDSCs from the same patients were positive for CXCR1
(Fig. 9 C). Next, we sorted CD15−CD14+HLA-DRlo/−CXCR1− and
CXCR1+ M-MDSCs from three patients with lung and pancreatic
cancers and assessed the ability of these cells to suppress T cell
proliferation in an allogeneic mixed leukocyte reaction. CXCR1−
cells had a potent suppressive activity, whereas CXCR1+ cells had
less or were not suppressive at all (Fig. 9 D). Thus, CXCR1−
M-MDSCs were bona fide M-MDSCs, whereas CXCR1+ cells did
not fit the basic criteria of M-MDSCs. Since mouse MLPGs had
the same feature (lack of suppressive activity despite phenotypic
criteria of M-MDSCs), we investigated the ability of CXCR1+
M-MDSCs to differentiate to neutrophils. CD15−CD14+HLA-DRhi
monocytes and CXCR1+ and CXCR1− M-MDSCs were sorted from
the peripheral blood of patients with non–small cell lung cancer
and cultured for 4 d on OP9 feeder cells in the presence of
GM-CSF and G-CSF (Anani and Shurin, 2017). Practically all cells
differentiated from monocytes and CXCR1−CD14+CD15−HLADR−/lo M-MDSCs had morphological features of macrophages.
In contrast, a substantial proportion of cells with the morphology
of neutrophils were detected after the culture of CD15−CD14+HLADR−/lowCXCR1+ cells (Fig. 9 E). To verify that these cells were indeed neutrophils, we evaluated the activity of naphthol AS-D
chloroacetate esterase, a specific marker of human neutrophils.
Practically no esterase-positive cells were found among cells differentiated from monocytes and CXCR1− M-MDSCs, whereas
esterase-positive cells were readily detectable among cells differentiated from CXCR1+ monocytic cells (Fig. 9 E). Overall, ∼20%
of cells differentiated from CXCR1+CD14+CD15−HLA-DR−/lo
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Figure 8. Mechanism of MLPG expansion in TB mice. (A) Proliferation of BM MLPGs from naive and EL-4 TB mice in vitro assessed by BrdU uptake (left) and
3H thymidine incorporation (right) after 20 h of culture in complete RPMI without cytokines (n = 4). (B) Frequency of Annexin V+ BM MLPGs from naive and EL-4
TB mice after 20 h of culture in complete RPMI without cytokines (n = 7). (C) Frequency of Annexin V+ BM MLPGs from naive and EL-4 TB mice cultured in the
presence of 5% vol/vol EL-4 TES for 20 h in complete RPMI without cytokines (n = 4). (D) Proliferation of BM WT and Rb1 KO MLPGs in vitro, assessed by BrdU
uptake after 20 h of culture in complete RPMI without cytokines (n = 4). (E) Proliferation of BM WT and Rb1 KO MLPGs in vivo, assessed by BrdU uptake.
Frequency of BrdU+ cells was evaluated 4 h after i.p. injection of BrdU (n = 3). (F) Frequency of Annexin V+ BM WT and Rb1 KO MLPGs 20 h after culture in
complete RPMI without cytokines (n = 6). (G) Numbers of cells generated from EL-4 BM CD11b+Ly6ChiLy6G−CD117− M-MDSCs and CD11b+Ly6ChiLy6G−CD117+
MLPGs after 3-d culture in RPMI (supplemented or not with FBS) with or without addition of the indicated cytokines. Dashed line, starting number of cells (n = 6);
Lip, lipids. (H) Frequency of live cells from the experiments described in G (n = 6). (I) Frequency of Ly6G+ cells generated from the MLPG cultures described
in G (n = 6). (J) Numbers of cells generated from EL-4 BM MLPGs cultured for 3 d in serum-free media (SFM) with or without the indicated cytokines. Complete
RPMI was used as a positive control (n = 4). P values were calculated by two-tailed Student’s t test. *, P < 0.05; **, P < 0.01; ****, P < 0.0001. Mean and SD
are shown.

cells were represented by neutrophils, whereas neutrophils
were practically undetectable among cells differentiated from
monocytes and bona fide CXCR1− M-MDSCs (Fig. 9 F). These
results suggest that human CXCR1+CD14+CD15−HLA-DR−/lo
monocytic cells are enriched for MLPGs.

Discussion
In this report, we describe the existence of a population of
committed GPs that belongs to the monocytic lineage, named
MLPGs. These cells were either present at very low numbers or
completely absent in tumor-free mice in the steady state, but
were markedly expanded in the BM and spleens of TB mice. They
expressed the CD11b and Ly6Chi markers and lacked expression
of Ly6G, which would define them as classic inflammatory
monocytes in control mice or M-MDSCs in TB mice (Bronte et al.,
Mastio et al.
Monocytic precursors of granulocytes in cancer

2016). However, MLPGs lacked suppressive activity and were
characterized by the expression of c-kit (CD117). C-kit expression
is associated with progenitors of granulocytes or monocytes/
macrophages such as CMPs (Lin−IL7Rα−c-Kit+Sca-1−CD34+CD16/
32lo) and GMPs (Lin−IL7Rα−c-Kit+Sca-1−CD34+CD16/32hi; Akashi
et al., 2000). CD117 was also present on committed neutrophil
precursors (GPs) that can be either Ly6Clo or Ly6Cint. Using fate
mapping experiments and gene expression profile analysis,
we demonstrated that CD11b+Ly6CintLy6G−CD117+SiglecF−CCR2−
cells were indeed committed GPs, which were very similar to the
preNeu granulocyte progenitors described previously (Evrard
et al., 2018). The main challenge was to determine whether
MLPGs were indeed monocytic cells rather than a subset of GPs
with a high Ly6C expression.
Several lines of evidence support the conclusion of the
monocytic origin of MLPGs distinct from that of GPs. (i)
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Figure 9. MLPGs in humans. (A) Analysis of 619 genes significantly differentially expressed (FDR <5%) in M-MDSCs compared with monocytes from lung
cancer patients. Expression heatmap for a gene subset specific to neutrophils and monocytes/macrophages and top significant genes. Mono, monocyte.
(B) Functions significantly enriched among significant genes as identified by Ingenuity Pathway Analysis. (C) Proportion of CXCR1+ cells among healthy donor
(HD) and prostate cancer patient CD14+CD15−HLA-DRhi monocytes (Mon) and among CD14+CD15−HLA-DRlo/− M-MDSCs from the same patients. Results from
individual patients are shown (n = 8). Mean and SD are shown. ****, P < 0.0001 by two-sided Student’s t test. Mon, monocyte. (D) CXCR1+CD14+CD15−HLADRlo/− and CXCR1− CD14+CD15−HLA-DRlo/− M-MDSCs were sorted from the peripheral blood of cancer patients and used in a three-way allogeneic mixed
leukocyte reaction using dendritic cells (DC) and T cells from unrelated donors. T cell proliferation was measured in triplicate, and mean and SD are shown. P
values were calculated by Student’s t test. *, P < 0.05; **, P < 0.01; ***, P < 0.0001. (E) Differentiation of neutrophils from the indicated monocytic populations
after 4-d culture on OP-9 feeder cells with G-CSF and GM-CSF. A typical example is shown. May-Grünwald-Giemsa staining on the left; staining for naphtholAS-chloroacetate esterase (napththol-AS-chlor.acet. Est) activity on the right. Four experiments with the same results were performed. Scale bar, 20 µm.
(F) Frequency of neutrophils differentiated from monocytes and M-MDSCs isolated from cancer patients after 4 d culture on OP-9 feeder cells with G-CSF and
GM-CSF. Values for each patient are shown (n = 4). In all experiments, mean and SD values are shown. P values were calculated by Student’s t test. *, P < 0.05;
**, P < 0.01. cpm, counts per minute.

MLPGs had a very distinct genomic profile from GPs. It
correlated with monocytes, MDPs and common dendritic cell
progenitors, whereas the genomic profile of GPs correlated
only with the profiles of granulocytes. Moreover, after filtering for only genes differentially expressed between
MLPGs and GPs, the MLPG profile correlated only with those
of monocytes/M-MDSCs, whereas the GP gene expression
profile correlated only with those of granulocytes/PMNMDSCs. (ii) The genomic profile of MLPGs was also distinct
from that of GMPs. (iii) MLPGs expressed the monocytic
cell–specific marker CX3CR1 at a level similar to that found
in monocytes/M-MDSCs, whereas GPs had very low expression of this marker, as in neutrophils/PMN-MDSCs. (iv)
MLPGs differentiated to neutrophils similarly in the presence of GM-CSF and M-CSF. (v) Deletion of the Irf8 transcription factor caused a massive accumulation of GPs but
resulted in a decreased amount of MLPGs. In contrast, Rb1
deletion resulted in the accumulation of MLPGs but did not
affect GPs.
Under steady state conditions, granulocyte differentiation in mice proceeds through a well-defined CMP–GMP–GP
pathway, which is negatively regulated by IRF8. Monocytes
differentiate from GMPs, MDPs, or common myelolymphoid
progenitors, which are positively regulated by IRF8 (Kurotaki
et al., 2014). It appears that under steady state conditions,
there is a very small (and likely inconsequential for the generation of granulocytes) population of monocytic cells that can
differentiate into granulocytes. In our study, MLPGs were
downstream of GMPs. In a recent study, differentiation of
monocytes from GMPs independently of MDPs was described
(Yáñez et al., 2017). Interestingly monocytes derived from
GMPs had expression of genes specific for neutrophils (Yáñez
et al., 2017). It is tempting to suggest that the “neutrophil-like”
subset of monocytes from that study may contain MLPGs. In
contrast to control mice, in cancer, the MLPG population expanded extensively and substantially contributed to PMNMDSC accumulation (Fig. 10). It appears that down-regulation
of Rb1 could be a major mechanism of this expansion. Although the molecular mechanisms of this effect warrant further elucidation, more active proliferation of MLPGs could
contribute to this phenomenon. This would be consistent with
the overall role of Rb1 as a checkpoint in the cell cycle (Calo
et al., 2010). MLPGs from Rb1 KO and TB mice showed similar
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enhanced proliferation compared with WT and naive tumorfree mice. However, it may be only part of the mechanism,
since Rb1 did not affect MLPG survival but only proliferation,
whereas in TB mice, MLPGs demonstrated both better survival and proliferation than cells from naive mice.
Our data demonstrated that MLPGs do not contribute to
granulocyte differentiation in naive mice but are important
precursors of PMN-MDSCs in TB mice, based on the following
findings. (i) All transplantable tumor models and most GEMs of
cancer demonstrated accumulation of MLPGs in BM as well as in
the spleen, the site of extramedullary hematopoiesis in mice. (ii)
The strength of this accumulation corresponded to the levels of

Figure 10. Schema of neutrophil differentiation in cancer. In the steady
state, neutrophil differentiation is the end point of the MPP–CMP–GMP–GP
pathway. This pathway is negatively regulated by the IRF8 transcription
factor. In steady state, the MLPG contribution to the neutrophil and monocyte pool is minimal. In cancer, down-regulation of IRF8 and Rb1 leads to
expansion of both PMN-MDSC progenitors: GPs and their monocytic counterparts MLPGs. MLPGs, in some models, may contribute to 50% of the PMNMDSC pool. CMLP, common myelolymphoid progenitor; HSC, hematopoietic
stem cell; Mon, monocyte; MPP, multipotent progenitor.
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PMN-MDSC expansion in these models. (iii) Depletion of
monocytic cells by targeting CX3CR1 reduced the presence of
PMN-MDSCs by half in EL-4 and LL2 TB mice, without affecting
granulocyte numbers in control mice.
MLPGs from TB may be endowed with some intrinsic
ability to generate immunosuppressive PMN-MDSCs. Further
experiments would be required to figure out the suppressive
mechanism of MLPG-derived PMN-MDSCs. Dramatic expansion of MLPGs in spleens of TB mice supported the important
role of extramedullary hematopoiesis in MDSC accumulation.
We tested the relative contribution of the spleen to MDSC
accumulation in tumors. Previous studies demonstrated that
splenectomy reduced the presence of MDSCs in tumors (Lecut
et al., 2009; Kawano et al., 2015; Levy et al., 2015; Schug et al.,
2015). This would directly support the concept of our study,
where MLPGs were found to be dramatically expanded in
spleen. However, in one study, a splenectomy was performed
21 d after tumor inoculation and significantly reduced tumor
growth (Levy et al., 2015). In another study, a splenectomy
was performed 10 d before tumor inoculation (Kawano et al.,
2015), whereas in several other studies splenectomy was
performed at the time of tumor inoculation (Lecut et al., 2009;
Schug et al., 2015). We were concerned with the possibility
that such invasive surgery, as well as removal of the spleen at
the time of myeloid cell expansion, may not accurately recapitulate the possible contribution of the spleen to the expansion of MLPGs and PMN-MDSCs. Therefore, we performed
splenectomy 10 wk before tumor inoculation to allow for full
recovery. Our data indicated that in the absence of the spleen,
BM provided full support for the expansion of functionally
potent M-MDSCs and PMN-MDSCs in tumors. Thus, although
the role of the spleen in MDSC production is unquestionably
important, the BM can provide sufficient support for MDSC
accumulation.
Thus, this study demonstrated the existence of monocytic
precursors of granulocytes that are expanded in cancer, not only
in mouse models, but also in cancer patients. Mechanistic
studies in mouse models demonstrated that this myeloid differentiation pathway is controlled by the down-regulation of
Rb1, which substantially contributed to the accumulation of
PMN-MDSCs. This opens a new opportunity for selective targeting of abnormal myelopoiesis in cancer.

Mice and tumor models
All experiments with mice were approved by the Wistar Institute Animal Care and Use Committee. The mice were kept under
pathogen-free conditions. Female C57BL/6 CD45.1+, C57BL/6
CD45.2+, and Balb/c mice (age 6–8 wk) were purchased from
Charles River Laboratories. OT-I TCR-transgenic mice (C57Bl/6Tg(TCRaTCRb)1100mjb; 4–6 wk old), female Pmel TCRtransgenic mice (B6.Cg-Thy1a/Cy Tg(TcraTcrb)8Rest; 4–6 wk
old), CX3CR1CreER mice (B6.129P2(Cg)-Cx3cr1tm2.1(cre/ERT2)Litt/
Wgan), and ROSA-DTRfl/fl (CBy.B6-Gt(ROSA)26Sortm1(HBEGF)
Awai) were purchased from the Jackson Laboratory. TRAMP
mice were bred in Dr. L.R. Languino’s laboratory (Thomas Jefferson University, Philadelphia, PA; Chapman et al., 2011).
CX3CR1CreERROSA-DTRfl/fl mice were generated by crossing a
male CX3CR1CreER with a female ROSA-DTRfl/fl. Ret mice were
obtained from Dr. Umansky (German Cancer Center, Heidelberg, Germany). Transgenic KPC mice (Bayne et al., 2012), Rb1
KO (Youn et al., 2013), and Rb TKO (Viatour et al., 2008) mice
were described previously. IRF8−/− mice on a C57BL/6 background were generated as previously described (Holtschke et al.,
1996) and originally were a kind gift of Dr. K. Ozato (National
Institutes of Health, Bethesda, MD). Rb1-GFP reporter mice were
kindly provided by Dr. J. Sage (Stanford University, Stanford,
CA). They were generated by inserting an eGFP cassette at the
start codon of Rb (Burkhart et al., 2010). The eGFP reporter
construct also included two polyadenylation signals that prevent
downstream expression of the coding Rb transcript from the
bacterial artificial chromosome. These mice were backcrossed to
C57BL/6 background for 10 generations. For the experiments
described in this study, age- and sex-matched littermates were
used as controls. To induce CX3CR1+ monocytic cell depletion
in CX3CR1CreERROSA-DTRfl/fl mice, mice received Tm (SigmaAldrich) as a solution in corn oil (Sigma-Aldrich) and ethanol at
20 mg/ml. Animals received five 4-mg doses of Tm (200 µl) by
gavage for five consecutive days. At day 6, the coinjection of Tm
and DT (Sigma-Aldrich) started. Mice received two i.p. doses of
DT (1 µg in 200 µl of PBS) every other day.
For splenectomy, the surgical site was sterilely prepared and
draped after anesthesia. A 1-cm paramedian incision was made
over the left upper quadrant. The spleen was identified, small clips
were applied to the vascular pedicles, and the spleen was removed.
For sham operations, a laparotomy incision was made, but no
splenic tissue was resected. For adoptive transfers experiments,
mice were sublethally irradiated with a single dose of 450 cGy.

Materials and methods
Human subjects and samples
Samples of peripheral blood from healthy volunteers were
collected at the Wistar Institute, while samples from patients
were collected at the Helen F. Graham Cancer Center, part of
the Christiana Care Health System. The study was approved
by the Institutional Review Boards of the Christiana Care
Health System at the Helen F. Graham Cancer Center and the
Wistar Institute. All patients signed approved consent forms.
Six healthy volunteers and 11 patients with previously untreated stage II–III melanoma or non–small cell lung cancer
were enrolled. This cohort included four women and six men,
ages 34–72 yr.
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Cell lines
Cell lines including EL-4 lymphoma, Lewis lung carcinoma,
B16F10 melanoma, CT26 colon carcinoma, and OP9 stromal cells
were obtained from ATCC. All except OP9 cells were maintained
in DMEM supplemented with 10% FBS (Sigma-Aldrich) and 1%
penicillin-streptomycin (Thermo Fisher Scientific) at 37°C with
5% CO2. OP9 cells were maintained in MEMα without nucleosides (Thermo Fisher Scientific) supplemented with 20% FBS
and 1% penicillin-streptomycin at 37°C with 5% CO2. Tumor cells
were injected subcutaneously at 5 × 105 cells (diluted in 100 µl of
PBS) per mouse to form tumors 1.5 cm in diameter within 3 wk
of injection.
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Reagents
A list of reagents is provided in Table S1.
Cell isolation and culture
For the BM, one leg (one tibia and one femur) was used (absolute
numbers given are for one leg). When a higher number of cells
was required (especially for progenitor populations such
MLPGs, GPs, and GMPs), all bones were used (legs, pelvises,
sternum, and spine). Bones cleaned of muscular tissues are
crushed with a sterile mortar and pestle in a cold solution of cell
suspension buffer (CSB): 1× PBS (Thermo Fisher Scientific), 1%
FBS, and 2 mM EDTA (Thermo Fisher Scientific). The cell suspension was then filtered through a 70-µm strainer (Thermo
Fisher Scientific) placed on a conical 50-ml Falcon tube. For
spleens, the organ was put in a 70-µm strainer placed on a
conical 50-ml Falcon tube and cut into small pieces. These pieces
were then ground against the cell strainer using the plunger of a
5-ml syringe and washed several times with cold CSB. BM and
spleen cell suspensions were then centrifuged at 1,500 rpm at
4°C, the supernatant was removed, and red blood cells were lysed
in ammonium chloride lysis buffer for 5 min at room temperature. Cells were washed and resuspended in cold CSB. Single-cell
suspensions from tumor tissues were prepared using the mouse
tumor dissociation kit (Miltenyi Biotec) according to the manufacturer’s recommendations, with an additional red blood cell
lysis step as described above.
Sorted cells (≤105 cells per well for MLPGs) were cultured in
24-well plates in 1 ml total volume in the presence of 20 ng/ml
recombinant GM-CSF (Thermo Fisher Scientific). In some experiments, 20 ng/ml G-CSF (Peprotech) or M-CSF (Peprotech)
were also used. Cells were cultured in complete RPMI: RPMI
1640 (Thermo Fisher Scientific) supplemented with 10% FBS, 1%
penicillin-streptomycin, and 1× 2-mercaptoethanol (Thermo
Fisher Scientific). 5, 10, or 20% vol/vol TES from EL-4 tumors
was used in some experiments. For some experiments, cells
were kept in complete RPMI only, without addition of cytokines.
For 3H thymidine incorporation for MLPG proliferation, cells
were kept in complete RPMI without extra cytokines in 230 µl
total volume including 1 µCi of 3H thymidine (PerkinElmer) in a
U-bottom 96-well plate.
In vivo transfer of MLPGs and GMPs
EL-4 TB female C57Bl/6 CD45.1+ recipient mice were irradiated
with a single dose of 450 cGy and set aside for a few hours to
recover. During the recovery time, EL-4 TB female C57Bl/6
CD45.2+ donor mice were used to isolate the different progenitors from the BM. After sorting, collected CD45.2+ progenitor
cells were resuspended in 100 µl of PBS and injected i.v. into the
irradiated EL-4 TB CD45.1+ recipient mice. In most experiments
with MLPG and GP differentiation, we used ∼2 × 106 cells. For
GMP differentiation after 24 h, we used 5 × 105 cells.
Preparation of TESs
TESs were prepared from excised nonulcerated EL-4 tumors
∼1.5 cm in diameter. A small tumor piece (5–10 mm2) was
harvested, minced into pieces <3 mm in diameter, and resuspended in complete RPMI without extra cytokines. After
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16–18 h of incubation at 37°C with 5% CO2, the cell-free supernatant was collected using 0.22-µm filters (EMD Millipore) and
kept at −80°C.
Microarrays of mouse cells
1–2 million cells were lysed in 1 ml of Tri-Reagent (SigmaAldrich), and RNA was extracted using phase separation and
isopropanol precipitation as recommended by the vendor.
RNA quality was validated using the Agilent Bioanalyzer and
the RNA Nano chip (Agilent), and quantity was determined
using the NanoDrop 2000 Spectrophotometer (Thermo Fisher
Scientific). A constant amount (100 ng) of total RNA was
amplified using the Illumina approved RNA amplification kit
(Epicentre). Samples were processed in batches of six on Illumina Mouse WG6v2 microarrays for mRNA expression.
Data were exported for analysis using Illumina GenomeStudio
software. GenomeStudio was used to export expression levels
and detection P values for each probe of each sample. Signal
intensity data were quantile normalized, log2-transformed,
and mean centered, and genes that showed insignificant detection P values (P > 0.05) in all samples were removed from
further analysis. Expression level comparisons between two
groups were done using two-sample significance analysis of
microarrays (SAM; Zhang, 2007), and correction for multiple
testing to estimate FDR was done as described (Storey and
Tibshirani, 2003), with FDR <5% used as a significance
threshold. Expression data for granulocytes, monocytes, and
stem cells were downloaded from the Immgen Consortium,
and overlap was done based on Entrez ID mean centered for
further analysis. Two-dimensional clustering was done using
t-distributed stochastic neighbor embedding (tSNE; Kim and
Cohen, 2016). Matlab package with initial solution parameter
set at 20 and perplexity parameter set at 30 was used.
RNA-seq of human cells
Cell pellets containing 500,000 to 1 million cells were lysed in
300 µl of Tri-Reagent, and RNA was extracted using the DirectZol RNA Mini-Prep Kit (Zymo Research), including an oncolumn DNaseI treatment. RNA quality was validated using
the Agilent Tapestation and the High Sensitivity RNA Screentape (Agilent), and quantity was determined using the Qubit 2.0
Fluorometer (Thermo Fisher Scientific). 39 mRNA-seq libraries
were generated from DNaseI-treated total RNA using the
QuantSeq FWD Library Preparation kit (Lexogen), according to
the manufacturer’s directions. Overall library size was determined using the Agilent Tapestation and the DNA 5000
Screentape, and libraries were quantitated using real-time PCR
(Kapa Biosystems). Libraries were pooled and denatured, and
high-output, single-read, 75–base pair next-generation sequencing was done on a NextSeq 500 (Illumina). Data were
aligned using bowtie2 (Wan et al., 2004) and RSEM v1.2.12
software (Li and Dewey, 2011) against mm10 genome and genelevel read counts, and reads per kilobase of transcript per million mapped read values on gene level were estimated for
ensemble transcriptome. DESeq2 (Love et al., 2014) was used to
estimate significance between any two experimental groups.
Overall changes were considered significant if they passed FDR
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<5% thresholds. Gene set enrichment analysis was done using
Ingenuity Pathway Analysis software (Qiagen) based on
“Functions” and “Upstream Regulators.” Only categories with
≥20 genes enriched at P < 10−10 with significantly predicted
activation scores (|Z-score| > 2) were reported. Data were
submitted to the Gene Expression Omnibus under accession
nos. GSE131516 for mouse microarray and GSE131552 for human RNA-seq.
May-Grünwald-Giemsa and Wright-Giemsa staining
105 to 2 × 105 cells were resuspended in 100 µl of PBS and spun
down at 800 rpm for 5 min using a Shandon Cytospin 2 machine
and slides. May-Grünwald (Sigma-Aldrich) and Giemsa stain
(Sigma-Aldrich) were used according to the manufacturer’s
recommendations. For Wright-Giemsa pictures, the Harleco
Wright-Giemsa stain pack (EMD Millipore) was used according
to the manufacturer’s recommendations. The cells were imaged
with a Nikon Eclipse E600 microscope.
Flow cytometry
All incubations were performed for 15 min at 4°C in the dark,
and centrifugations were done at 1,500 rpm at 4°C for 5 min,
unless recommended otherwise by the manufacturer. Usually,
≤106 cells were incubated with Fc-block (BD Biosciences; clone
2.4G2; 553142) in 50 µl of CSB, then washed in CSB and spun
down before cell surface staining with additional antibodies.
After the last incubation, cells were washed in CSB, spun down,
and resuspended in 400 µl of CSB before acquisition. Cells were
run on an LSRII flow cytometer (BD Biosciences), and data were
analyzed by FlowJo (Tristar). For sorting, both FACS Aria II (BD
Biosciences) and MoFlo Astrios EQ (Beckman Coulter) were
used. The antibodies, dyes, and kits used are described in
Table S1.
Human M-MDSC/monocyte isolation, culture, and staining
1.07 × 105 OP9 cells were plated in a 12-well plate the day before
sorting. The low-density PBMC fraction was isolated by centrifugation over a Ficoll-Paque Plus density gradient (GE
Healthcare Life Sciences). The PBMC layer was collected, and
cells were washed and stained with CD14-APC-Cy7, HLA-DRAPC, CD15-PE, and Aqua Live/Dead Fixable 405. After sorting,
MEMα without nucleosides was removed from the OP9 cells
wells and replaced with IMDM (Thermo Fisher Scientific) supplemented with 20% FBS and 1% penicillin–streptomycin. Up to
3.5 × 105 sorted cells were added per well in a total volume of
3 ml of IMDM in the presence of 100 ng/ml of G-CSF and 25 ng/
ml of GM-CSF (Peprotech) or 100 ng/ml of M-CSF. At day 3, 2 ml
of fresh media supplemented with fresh cytokines were added
on the top. At day 4, cells were harvested by pipetting up and
down. Human CD45+ cells were separated from murine OP9 cells
by magnetic separation using biotinylated anti-human CD45
antibody (Miltenyi Biotec), streptavidin-coated microbeads
(Miltenyi Biotec), and magnetic-activated cell sorting columns
(Miltenyi Biotec) according to the manufacturer’s instructions.
Cells were then stained with the May-Grünwald-Giemsa kit or
the naphthol AS-D chloroacetate esterase (Sigma-Aldrich) kit or
stained for flow cytometry.
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Suppression assay
TAMs, M-MDSCs, and PMN-MDSCs were isolated from tumor
tissues by either sorting (TAMs and M-MDSCs) or magnetic
separation (PMN-MDSCs). For PMN-MDSC isolation, cells were
labeled with biotinylated anti-Ly6G antibody (Miltenyi Biotec),
incubated with streptavidin-coated microbeads (Miltenyi Biotec), and separated on magnetic-activated cell sorting columns.
Ly6G+ cells obtained after MLPG cultures were isolated in the
same way. After isolation, cells were plated in U-bottom 96-well
plates in triplicate in complete RMPI without extra cytokines.
They were cocultured at different ratios with total splenocytes
from Pmel or OT-1 transgenic mice in the presence of cognate
peptides: OT-1, SIINFEKL; Pmel, EGSRNQDWL. Cells were incubated for 48 h, and then 3H thymidine (PerkinElmer) was
added (1 µl/well) and incubated overnight. Samples were
counted with a TopCount NXT instrument (PerkinElmer).
Quantitative real-time PCR (qRT-PCR)
RNA was extracted using Total RNA Kit I (Omega) according to
the manufacturer’s instructions, including an on-column DNase
digestion. cDNA was generated with high-capacity cDNA reverse transcription kit (Applied Biosystems). qRT-PCR was
performed using Power SYBR green PCR master mix (Applied
Biosystems) in 96-well plates in triplicate. Plates were read on a
QuantStudio 6 Flex real-time PCR system (Applied Biosystems).
The murine primers used were Actb: forward, 59-CCTTCTTGG
GTATGGAATCCTGT-39, and reverse, 59-GGCATAGAGGTCTTT
ACGGATGT-39; Irf8: forward, 59-AGAACAAAAATGCAAGCTGGG
C-39, and reverse, 59-GCTCCTCTTGGTCATACCCAT-39.
Statistical analysis
Statistical analyses were performed using two-tailed Student’s
t test or Mann–Whitney U test and Prism 5 software (GraphPad).
Paired t test was used since data were normally distributed. All
the data are presented as mean ± SD unless noted otherwise, and
P values <0.05 were considered significant.
Online supplemental material
Fig. S1 describes differentiation of MLPGs and GPs in vitro and
in vivo. Fig. S2 depicts the gene signatures of MLPGs and GPs.
Fig. S3 shows characteristics of MLPGs in naive and tumor-free
mice. Fig. S4 describes the contribution of spleens in PMNMDSC accumulation in TB mice. Fig. S5 depicts data on MLPGs
and GPs in mice with targeted depletion of monocytic cells.
Table S1 presents a list of reagents used in this study.
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